Last edition
News about "GIPR agonist"
Ascletis Selects Oral ASC30-ASC48 Fixed-Dose Combination for Clinical Development in Obesity
Ascletis Pharma has selected its ASC30-ASC48 fixed-dose combination for clinical development as a once-daily oral therapy for obesity. The dual-target GLP-1R/GIPR candidate demonstrated encouraging preclinical efficacy, with an IND submission to the US FDA planned for Q4 2026.
GIPR Agonist | 17/07/2026 | By News Bureau | 158
Ascletis Submits 2 IND Applications to the US FDA for the Treatment of Obesity
Ascletis has submitted two IND applications to the US FDA for once-monthly obesity therapies, including ASC36_35, a first-in-class triple-target candidate acting on amylin receptor, GLP-1R and GIPR.
GIPR Agonist | 06/07/2026 | By Akanki | 121
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy